Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study

Anurag Mishra; Amarender Singh Puri; Sanjeev Sachdeva; Ashok Dalal

doi:10.5217/ir.2021.00106

Articles

Page Path: HOME > Intest Res > Volume 20(4); 2022 > Article

Original Article Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study: Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal; Intestinal Research 2022;20(4):445-451.
DOI: https://doi.org/10.5217/ir.2021.00106
Published online: February 8, 2022

Department of Gastroenterology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India

Correspondence to Amarender Singh Puri, Department of Gastroenterology, GIPMER, New Delhi 110002, India. Tel: +91-11-23234242, Fax: +91-11-23221835, E-mail: amarender.puri@gmail.com

• Received: July 29, 2021 • Revised: September 30, 2021 • Accepted: October 8, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,178 Views
488 Download
5 Web of Science
5 Crossref
4 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
Response to vaccine in patients with inflammatory bowel disease is lower than in the general population. We aimed to evaluate the efficacy of hepatitis B virus (HBV) vaccination in patients with ulcerative colitis (UC) versus controls.
Methods
We prospectively compared antibody response to HBV vaccination in 100 patients with UC versus controls. HBV vaccination was given to all the cases and controls at 0, 1 and 6 months. Anti-hepatitis B surface (anti-HBs) titers were then measured 4 weeks after the first and the third dose. Adequate immune response (AIR) was considered if the anti-HBs titer was >10 IU/L and effective immune response (EIR) if the anti-HBs titer was >100 IU/L.
Results
Median anti-HBs titer was lower in patients with UC than controls (67 IU/L vs. 105 IU/L, P<0.01). AIR and EIR were significantly lower in patients than in controls (82% vs. 96%, P=0.001; 41% vs. 66%, P<0.001, respectively). Univariate analysis showed that age <30 years, mild to moderate severity of disease, disease duration <5 years, male sex, post first dose anti-HBs titer >2 IU/L and non-exposure to corticosteroids, azathioprine and biologicals were predictors of AIR in patients with UC (P<0.05). Multivariate analysis revealed that only non-exposure to corticosteroids, azathioprine and biologicals, male sex, and disease duration <5 years were independent predictors of AIR.
Conclusions
Response rate to the HBV vaccination in patients with UC was significantly lower as compared to the controls. Male sex, shorter disease duration, and non-exposure to immunomodulators were independent predictors of AIR.
Keywords: Colitis, ulcerative; Hepatitis B; Vaccination; Adequate immune response; Effective immune response

INTRODUCTION

Patients with inflammatory bowel disease (IBD) have an increased risk of hepatitis B virus (HBV) infection due to malnutrition, blood transfusion, frequent use of immunosuppressants and procedures (endoscopic/surgical), which are usually required during the course of the disease [1]. According to one study almost half of the IBD patients would have at least one risk factor of hepatitis B transmission [2]. The mainstay of prevention of HBV and consequent acute and chronic liver disease is HBV vaccination [3,4]. The response to the vaccine in the patients of IBD seems to be considerably lower than in the general population, probably because of the aforementioned factors [1-5]. In healthy subjects nonresponse to the vaccination has been associated with multiple factors such as smoking, genetic factors, and advanced age [6]. According to the World Health Organization (WHO), anti-hepatitis B surface (anti-HBs) titer concentration ≥ 10 IU/L is considered a reliable marker of protection against HBV infection [7]. Among immunocompromised patients who respond to the vaccine, clinical HBV infection has been documented in those who do not maintain an anti-HBs titer ≥ 10 IU/L [1]. India falls in the intermediate endemicity zone for hepatitis B with a prevalence ranging between 2% and 7% and a disease burden of nearly 50 million [8]. However, there is no prospective study from India on the response of IBD patients to HBV vaccination. The aim of the present study was therefore to evaluate the efficacy and immunogenicity of the HBV vaccine in a cohort of patients with ulcerative colitis (UC) versus control subjects. To maintain homogeneity, we excluded patients with Crohn’s disease (CD) as the latter is much less prevalent and there is diagnostic confusion between tuberculosis and CD.

METHODS

1. Study

This prospective cohort study was conducted in the department of gastroenterology, between October 2018 to March 2020. We conducted this study in compliance with the principles of the Declaration of Helsinki. The study’s protocol was reviewed and approved by the Institutional Review Board of Maulana Azad Medical College (IRB No. MAMC/2018/55). Written informed consent was obtained from all the study subjects. One hundred patients of IBD (UC) with no prior history of HBV vaccination or HBV related infection were taken as cases and 100 non-IBD subjects, aged between 18 and 60 years who were attending the outpatient department for dyspepsia/irritable bowel syndrome or healthy subjects were taken as controls (Fig. 1). Exclusion criteria were evidence of current or past HBV infection, previously vaccinated patients, pregnant females, UC with concurrent malignancy, UC with toxic megacolon or acute severe colitis, HIV (human immunodeficiency virus), chronic kidney disease, and uncontrolled diabetes mellitus. The diagnosis of UC was made on the basis of the clinical presentation supported by appropriate endoscopic, radiological, and histological investigations. Detailed evaluation was made with respect to duration of the disease, severity, extent of the disease, presence or absence of extraintestinal manifestation and exposure to corticosteroids, immunomodulators and biologicals [9]. The diagnosis of dyspepsia and irritable bowel syndrome was made as per Rome IV criteria [10]. Blood samples were collected before vaccination to exclude HBV infection. After the first dose of the vaccine the study subjects were telephonically contacted to revert with anti-HBs titer. Similarly, they were telephonically contacted after the third dose for evaluation of the anti-HBs titer. The subjects who did not come back after the first or the third dose were excluded from the study. Both the cases and controls were tested for hepatitis B surface antigen (HBsAg), total anti-hepatitis B core antibody (anti-HBc Ab), anti-HBs titer, and liver function test. After exclusion of HBV infection, HBV vaccination (Revac-B/Bharat biotech/purified hepatitis B type surface antigen 1 mL) was injected in the deltoid to all the cases and controls as per standard WHO recommendations at 0, 1, and 6 months [11]. Adequate immune response (AIR) was defined as anti-HBs titer > 10 IU/L and effective immune response (EIR) was defined as anti-HBs titer > 100 IU/L [1-7]. A serum anti-HBs level below 10 IU/L was counted as a nonresponder. If any case and control was lost to follow-up within 1 month after vaccination then that subject was excluded from the study.

2. Statistical Analysis

Data analysis was done by SPSS software version 25 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean and standard deviation if they were normally distributed. Median and interquartile ranges were used for continuous variables when they were not normally distributed. To compare paired nonparametric data Wilcoxon signed-rank test was used. Categorical variables were expressed as proportions and were analyzed by the chi-square test or the Fisher exact test. Continuous variables were compared by Students t-test or Mann-Whitney U test where indicated. Multivariate logistic regression analysis was performed for the variables found statistically significant in the univariate analysis. A P-value of < 0.05 was considered to be statistically significant.

RESULTS

The mean age of the patients in the UC group (59 males) and controls (54 males) was 32.8 ± 11.4 years and 36.0 ± 10.3 years respectively (P=0.04). In the UC group, the proportion of patients with mild, moderate, and severe disease were 14 (14%), 69 (69%), and 17 (17%), respectively. The mean duration of UC was 60.3 months. The extent of the disease was E1 (12%), E2 (25%), and E3 (63%). Extraintestinal manifestations were documented in 6 patients (6%; peripheral arthropathy in 5 and episcleritis in 1 patient). Sixty-four patients each had exposure to corticosteroids and thiopurine. None of the patients were taking steroids at the time of vaccination. Only 10% of patients had been exposed to biologicals (infliximab). Their findings are summarized in Table 1.

The median anti-HBs titer was lower in the UC group than in the controls (67 IU/L [16–202] vs. 105 IU/L [57–229], respectively, P<0.002). The proportion of patients who achieved AIR was also lower in the UC group than in the controls (82% vs. 96%, P<0.001). EIR was also less frequent in the UC group than in the controls (41% vs. 66%, P<0.001). These observations are tabulated in Table 2.

AIR was achieved in 42 of the 46 patients (91.3%) cases with age ≤ 30 years as compared to 40 of the 54 patients (74.1%) in those with age > 30 years (P=0.036). Frequency of AIR in UC patients was higher in males as compared to females (89.8% vs. 70.7%, P=0.014).

AIR was achieved in 46 of the 64 patients (72%) of the UC patients who had history of exposure to corticosteroids as compared to 36 patients (100%) (P<0.001) who were not exposed to corticosteroids. In patients with UC with history of thiopurine exposure, AIR was achieved in 46 of the 64 patients (72%) as compared to 36 patients (100%) who were not exposed to thiopurines (P<0.001). In UC patients with prior history of exposure to both corticosteroid as well as azathioprine, AIR was achieved in 39 of the 57 (68.4%) patients as compared to 43 patients (100%) who were not exposed to this combination (P<0.001). In patients with UC with history of exposure to biologicals, AIR was achieved in 5 of the 10 patients (50%) cases as compared to 77 of the 90 patients (85.5%) who were not treated with biologicals (P=0.016).

AIR was achieved in 72 of the 83 patients (86.8%) with mild to moderate disease activity as compared to 10 of the 17 patients (58.8%) in those with severe disease activity (P=0.017). AIR was achieved in 33 of the 37 patients (89.2%) with limited colitis as compared to 49 of the 63 patients (77.8%) with pancolitis (P=0.185). AIR was significantly higher in the patients with ≤ 5 years disease duration than those with duration > 5 years (88.2% vs. 68.8%, P=0.018). AIR was achieved in 59 of the 76 patients (77.6%) if the post first dose titer was ≤ 2 lU/L as compared to 23 of the 24 patients (95.8%) in whom the post first dose titer > 2 lU/L (P=0.034).

Only 5 patients in the UC group had anti-HBs titer > 10 IU/L after the first dose as compared to 15 patients in the control group.

On applying univariate analysis it was observed that age < 30 years, mild to moderate severity of disease, disease duration < 5 years, male sex, post first dose anti-Hbs titer > 2 IU/L and non-exposure to corticosteroid, azathioprine, and biologicals were predictors of AIR in patients with UC (P<0.05). On applying multivariate analysis we found that non-exposure to corticosteroids, azathioprine, biologicals, male sex, and disease duration < 5 years were all independent predictors of AIR in patients with UC (Table 3). None of the patients (UC) or the controls had any serious adverse event following the vaccination.

DISCUSSION

This is the largest prospective cohort study from Asia which compares the response of the standard 3-dose HBV vaccination in patients with IBD (UC) compared to controls. A prior prospective study from Korea of 73 patients included both vaccine nonresponders and vaccine naïve patients with both CD and UC [12]. Only 29 patients in this study had the complete vaccination schedule of 3 doses which is considerably lesser than the sample size in the current study. In the current study, both AIR and EIR were significantly lower in patients with UC versus controls: 82% versus 96% and 41% versus 66%, respectively. The current study shows that female sex, disease duration > 5 years and exposure to corticosteroids, thiopurines and biologicals are independent predictors of poor response to the standard 3 dose vaccination in patients with UC.

Till now a total of 11 studies both prospective and retrospective have evaluated the response of HBV vaccination in IBD patients. Of these only 4 studies were prospective in design. Each of these 4 studies enrolled patients with both UC and CD, whereas our study was focused only on patients with UC. In these studies, the response rate of HBV vaccination varied from 34% to 89%. There is a near unanimous agreement on the fact that patients with IBD have a lower response rate to the standard 3 dose vaccination strategy as compared to the general population or non-IBD controls (Table 4). The vaccine response rate in the current study of 82% is well within this range.

Our findings are different from the published literature on 2 accounts. First, we showed that males had a higher response rate as compared to females. However, in the meta-analysis done by Jiang et al. [13] which evaluated 13 studies showed there was no sex differences in the response rate of vaccination. The same meta-analysis also showed that age younger than 26 years was associated with a higher response to the HBV vaccination. The variation from the latter observation in the current study could be explained by the fact that most of our patients in the UC were older as the mean age of our cohort was 32 years.

Patients on immunosuppressants have a poorer response to HBV vaccination. Nguyen et al. [23] showed there was a 65% lower chance of achieving AIR in patients on ≥ 2 immunosuppressant drugs. The maximum impact is seen in patients who have been exposed to anti-tumor necrosis factor (anti-TNF) drugs prior to vaccination. More recently Pratt et al. [22] found that patients exposed to infliximab were significantly less likely to possess anti-HBs levels ≥ 10 IU/L. In the current study, AIR was achieved in only 50% of the 10 patients who had been exposed to anti-TNF therapy which is in accordance with the meta-analysis done by Nguyen et al. [23] which clearly demonstrated that patients on immunomodulators or anti-TNF monotherapy had lower response rates to HBV vaccination.

A unique feature of our study was the determination of the anti-HBs titer after the first dose. This was done to determine if the patients in either the study group or the controls had received HBV vaccination but did not have any record or recollection of the same. Only 5% of the study group had an anti-HBs titer > 10 IU/L suggesting an anamnestic response. The corresponding value in the control group was significantly higher 15% (P<0.01). The implication of this observation is that these patients need not be given the remaining 2 doses of the HBV vaccine.

The current study has clinical implications for all those countries like China, India, and Korea which have a high disease burden of both IBD and hepatitis B. The prevalence of hepatitis B in India ranges between 1.4% and 2.7% in the general population [24]. Horizontal transmission accounts for nearly two-thirds of disease burden in India. The prevalence of UC in India is in the range of 40–45 per 100,000 [25]. Thus from an Indian perspective there is a large number of patients of UC who are potentially vulnerable to hepatitis B considering that the current population of India is about 1.38 billion. In a study from North America Melmed et al. [2] showed that less than 30% of IBD patients actually received the HBV vaccination despite having risk factors for acquiring hepatitis B infection. The corresponding figures for Asian countries like China and India are likely to be even lower than this. Considering the vast number of non-immunized IBD patients in these countries it would be prudent to start vaccinating the most vulnerable group, i.e., those with severe disease who are either on anti-TNF drugs or are being considered for biological therapy.

The current study has a few limitations. The post-vaccination follow-up period was limited. The moot point whether patients with a low antibody titer (< 100 IU/L) are protected against HBV infection due to an anamnestic response remains unanswered. Only if this point is proven beyond doubt is it worthwhile to aim for an EIR value ≥ 100 IU/L in these patients. The other limitation of our study is the small number (10%) of patients who were exposed to anti-TNF therapy. The low usage of biological therapy in India is related to the high cost of biological therapy and the lack of medical insurance coverage in most of the population [26]. There is therefore a need for multicentric studies having a significantly high number of IBD patients who have been exposed to biological therapy and subsequently evaluated for the efficacy of the HBV vaccination. Smoking may affect response to HBV vaccination but in our study it was not excluded which may be considered as a limitation. However the overall smoking rates in India are amongst the lowest in Asia. As per recent data, smoking percentage in India is only 14.8% as compared to other Asian countries like Indonesia, Korea, and Jordan where it ranges between 27% and 40.9% [27]. The smoking prevalence in females in Asia as per WHO data is only 2%. Therefore it is unlikely that the smoking status would have had a significant effect on the outcome of our study.

In conclusion, the current study shows that response rates (both AIR and EIR) to the HBV vaccination are considerably lower in South Asian patients with UC, who are female have longer duration of disease and have been exposed to immunosuppressants especially biologicals. Therefore the HBV vaccination status should be evaluated at the time of the initial diagnosis of IBD. In those who are not immunized, HBV vaccination should be administered preferably before exposure to immunosuppressive therapy.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Puri AS is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Not applicable.

Author Contribution

Conceptualization: Puri AS, Mishra A. Data curation: Mishra A. Formal analysis: Puri AS, Sachdeva S, Dalal A. Investigation: Puri AS, Mishra A. Methodology: Puri AS, Mishra A. Project administration: Mishra A. Supervision: Puri AS. Validation: Sachdeva S, Dalal A. Visualization: Sachdeva S, Dalal A. Writing –original draft: Puri AS, Mishra A. Writing – review & editing: Puri AS, Sachdeva S, Dalal A. Approval of final manuscript: All authors.

Fig. 1.

Study flowchart. HBsAg, hepatitis B surface antigen; anti-HBc Ab, anti-hepatitis B core antibody; anti-HBs, anti-hepatitis B surface; HBV, hepatitis B virus.

Table 1.

Baseline Characteristics of Patients with Ulcerative Colitis

Characteristics	Value (n = 100)
Age (yr)	32.8 ± 11.4
Sex
Male	59 (59)
Female	41 (41)
Disease severity
Mild	14 (14)
Moderate	69 (69)
Severe	17 (17)
Disease duration (mo)	60.3 ± 62.6
Extent of disease
E1	12 (12)
E2	25 (25)
E3	63 (63)
Exposure to immunosuppressants
Corticosteroids	64 (64)
Azathioprine/6-MP	64 (64)
Biologicals	10 (10)

Valuse are presented as mean±standard deviation or number (%).

6-MP, 6-mercaptopurine.

Table 2.

Response to Hepatitis B Virus Vaccination in the 2 Study Groups

Parameter	Case group (n = 100)	Control group (n = 100)	P-value
Anti-HBs titer (IU/L)	67 (16–202)	105 (57–229)	0.003
AIR (anti-HBs > 10 IU/L)	82 (82)	96 (96)	< 0.001
EIR (anti-HBs > 100 IU/L)	41 (41)	66 (66)	< 0.001

Valuse are presented as median (interquartile range) or number (%).

anti-HBs, anti-hepatitis B surface; AIR, adequate immune response; EIR, effective immune response.

Table 3.

Factors Affecting Adequate Immune Response-Multivariate Analysis

Variable	P-value
Sex (male vs. female)	0.043
Disease duration (≤ 5 yr vs. > 5 yr)	0.026
Exposure to corticosteroid	< 0.001
Exposure to azathioprine	0.001
Exposure to biological	0.023
Exposure to corticosteroid and azathioprine	< 0.001
Age (< 30 yr vs. > 30 yr)	0.570
Severity of disease (mild to moderate vs. severe)	0.182
Post first dose anti-HBs titer (≤ 2 IU/L vs. > 2 IU/L)	0.082

anti-HBs, anti-hepatitis B surface.

Table 4.

Response Rate of HBV Vaccination in Different Studies

Author (year)	Country	Study type	No. of IBD patients		HBV vaccine response (%)
Author (year)	Country	Study type	UC	CD	HBV vaccine response (%)
Vida Pérez et al. (2009) [14]	Spain	Retrospective	45	55	34
Altunöz et al. (2012) [1]	Turkey	Prospective	62	38	76
Gisbert et al. (2012) [15]	Spain	Prospective	31	69	60
Sempere et al. (2013) [16]	Spain	Retrospective	24	76	48
Andrade et al. (2015) [17]	Portugal	Prospective	21	79	76
Belle et al. (2015) [18]	France	Retrospective	20	80	79
Cekic et al. (2015) [19]	Turkey	Retrospective	52	48	57
Cossio-Gil et al. (2015) [20]	Spain	Retrospective	59	110	51
Etzion et al. (2016) [21]	Israel	RCT	21	79	75
Jiang et al. (2017) [13]	China	Meta-analysis	426	732	61
Chang et al. (2018) [12]	Korea	Prospective	28	45	89
Pratt et al. (2018) [22]	USA	Retrospective	137	246	55
Current study (2020)	India	Prospective	100	0	82

HBV, hepatitis B virus; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; RCT, randomized controlled trial.

REFERENCES

1. Altunöz ME, Senateş E, Yeşil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012;57:1039–1044.Article PubMed
2. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–1840.Article PubMed
3. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010;16:925–932.Article PubMed
4. Nguyen CT, Tran TT. Hepatitis vaccination and prophylaxis. Clin Liver Dis 2009;13:317–329.Article PubMed
5. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677–692.Article PubMed
6. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368–1375.Article PubMed
7. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:619–633.Article PubMed
8. Ray G. Current scenario of hepatitis B and its treatment in India. J Clin Transl Hepatol 2017;5:277–296.Article PubMed PMC
9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–1048.Article PubMed PMC
10. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–1407.Article
11. WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations. Vaccine 2010;28:589–590.Article PubMed
12. Chang JY, Jung SA, Moon CM, Kim SE, Jung HK, Shim KN. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res 2018;16:599–608.Article PubMed PMC
13. Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 2017;35:2633–2641.Article PubMed
14. Vida Pérez L, Gómez Camacho F, García Sánchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009;132:331–335.PubMed
15. Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:1379–1385.Article PubMed
16. Sempere L, Almenta I, Barrenengoa J, et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine 2013;31:3065–3071.Article PubMed
17. Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol 2015;30:1591–1595.Article PubMed
18. Belle A, Baumann C, Bigard MA, et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015;27:877–881.Article PubMed
19. Cekic C, Aslan F, Kirci A, et al. Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease. Medicine (Baltimore) 2015;94:e940.Article PubMed PMC
20. Cossio-Gil Y, Martínez-Gómez X, Campins-Martí M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol 2015;30:92–98.Article PubMed
21. Etzion O, Novack V, Perl Y, et al. Sci-B-VacTM Vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial. J Crohns Colitis 2016;10:905–912.Article PubMed PMC
22. Pratt PK Jr, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis 2018;24:380–386.Article PubMed
23. Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 2015;60:2446–2453.Article PubMed
24. Arora A, Singh SP, Kumar A, et al. INASL position statements on prevention, diagnosis and management of hepatitis B virus infection in India: the Andaman statements. J Clin Exp Hepatol 2018;8:58–80.Article PubMed PMC
25. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587–1590.Article PubMed PMC
26. Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol 2012;31:299–306.Article PubMed
27. World population review [Internet]. c2021 [cited 2019 Jun 1]. https://www.worldpopulationreview.com.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries
Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena
Journal of Crohn’s and Colitis.2026;[Epub] CrossRef
Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study
Rongbei Liu, Tingting Wu, Jian Tang, Hongjie Zhang, Yanyun Fan, Haibo Sun, Chen Xie, Qunyan Zhou, Hongzhen Xu, Yabi Zhu, Mei Ye, Xiaomin Shi, Feng Tian, Haiyan Shen, Dan Xu, Ying Zhou, Qian Cao
MedScience.2026;[Epub] CrossRef
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Rupert W. Leong, Anthony Sakiris, Arteen Arzivian, John David Chetwood, Thanaboon Chaemsupaphan, Miles P. Sparrow, Michael A. Kamm, Viraj Kariayawasam
Alimentary Pharmacology & Therapeutics.2025; 61(1): 132. CrossRef
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Vaccines.2024; 12(4): 364. CrossRef
Beyond the survey, to the ideal therapy for Asian
Ki Jae Jo, Jong Pil Im
Intestinal Research.2023; 21(3): 280. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study

Intest Res. 2022;20(4):445-451. Published online February 8, 2022

DOI: https://doi.org/10.5217/ir.2021.00106

XML Download

Figure

Related articles

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study

Fig. 1. Study flowchart. HBsAg, hepatitis B surface antigen; anti-HBc Ab, anti-hepatitis B core antibody; anti-HBs, anti-hepatitis B surface; HBV, hepatitis B virus.

Fig. 1.

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study

Characteristics	Value (n = 100)
Age (yr)	32.8 ± 11.4
Sex
Male	59 (59)
Female	41 (41)
Disease severity
Mild	14 (14)
Moderate	69 (69)
Severe	17 (17)
Disease duration (mo)	60.3 ± 62.6
Extent of disease
E1	12 (12)
E2	25 (25)
E3	63 (63)
Exposure to immunosuppressants
Corticosteroids	64 (64)
Azathioprine/6-MP	64 (64)
Biologicals	10 (10)

Parameter	Case group (n = 100)	Control group (n = 100)	P-value
Anti-HBs titer (IU/L)	67 (16–202)	105 (57–229)	0.003
AIR (anti-HBs > 10 IU/L)	82 (82)	96 (96)	< 0.001
EIR (anti-HBs > 100 IU/L)	41 (41)	66 (66)	< 0.001

Variable	P-value
Sex (male vs. female)	0.043
Disease duration (≤ 5 yr vs. > 5 yr)	0.026
Exposure to corticosteroid	< 0.001
Exposure to azathioprine	0.001
Exposure to biological	0.023
Exposure to corticosteroid and azathioprine	< 0.001
Age (< 30 yr vs. > 30 yr)	0.570
Severity of disease (mild to moderate vs. severe)	0.182
Post first dose anti-HBs titer (≤ 2 IU/L vs. > 2 IU/L)	0.082

Author (year)	Country	Study type	No. of IBD patients		HBV vaccine response (%)
Author (year)	Country	Study type	UC	CD	HBV vaccine response (%)
Vida Pérez et al. (2009) [14]	Spain	Retrospective	45	55	34
Altunöz et al. (2012) [1]	Turkey	Prospective	62	38	76
Gisbert et al. (2012) [15]	Spain	Prospective	31	69	60
Sempere et al. (2013) [16]	Spain	Retrospective	24	76	48
Andrade et al. (2015) [17]	Portugal	Prospective	21	79	76
Belle et al. (2015) [18]	France	Retrospective	20	80	79
Cekic et al. (2015) [19]	Turkey	Retrospective	52	48	57
Cossio-Gil et al. (2015) [20]	Spain	Retrospective	59	110	51
Etzion et al. (2016) [21]	Israel	RCT	21	79	75
Jiang et al. (2017) [13]	China	Meta-analysis	426	732	61
Chang et al. (2018) [12]	Korea	Prospective	28	45	89
Pratt et al. (2018) [22]	USA	Retrospective	137	246	55
Current study (2020)	India	Prospective	100	0	82

Table 1. Baseline Characteristics of Patients with Ulcerative Colitis

Valuse are presented as mean±standard deviation or number (%).

6-MP, 6-mercaptopurine.

Table 2. Response to Hepatitis B Virus Vaccination in the 2 Study Groups

Valuse are presented as median (interquartile range) or number (%).

anti-HBs, anti-hepatitis B surface; AIR, adequate immune response; EIR, effective immune response.

Table 3. Factors Affecting Adequate Immune Response-Multivariate Analysis

anti-HBs, anti-hepatitis B surface.

Table 4. Response Rate of HBV Vaccination in Different Studies

HBV, hepatitis B virus; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; RCT, randomized controlled trial.